Skye Bioscience, Inc. Common Stock (SKYE) Stock Price

SKYEStock

$1.55−86.64%52W

Market Cap$6.86M

P/E—

PEG Ratio—

Div yield—

Beta3.13

SKYE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-86.13%

Price vs S&P 500 (4W)-11.60%

VGM Score18.90

Book Value / Share (Quarterly)$2.05

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-8.83

Price vs S&P 500 (YTD)-86.09%

Gross Margin (TTM)39.29%

Net Profit Margin (TTM)-3.57%

EPS (TTM)$-7.93

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-7.93

EPS (Annual)$-11.28

ROI (Annual)-279.29%

Gross Margin (Annual)35.29%

Cash / Share (Quarterly)$2.39

ROA (Last FY)-197.52%

EBITD / Share (TTM)$-3.75

ROE (5Y Avg)-346.11%

Operating Margin (TTM)-7.14%

Cash Flow / Share (Annual)$-10.32

P/B Ratio0.76x

P/B Ratio (Quarterly)2.28x

Net Income / Employee (Annual)$-4,660,400

Net Interest Coverage (TTM)-45.68x

ROA (TTM)-201.79%

EPS Incl Extra (Annual)$-11.28

Current Ratio (Annual)3.30x

Quick Ratio (Quarterly)0.91x

3-Month Avg Trading Volume0.07M

52-Week Price Return-86.64%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.14

P/S Ratio (Annual)20.18x

Asset Turnover (Annual)2.27x

52-Week High$13.28

EPS Excl Extra (Annual)$-11.28

CapEx CAGR (5Y)-8.80%

26-Week Price Return-76.23%

Quick Ratio (Annual)3.24x

13-Week Price Return-70.13%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.95x

Enterprise Value$-1.50M

Asset Turnover (TTM)1.93x

Book Value / Share Growth (5Y)-3.96%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)0.00%

Cash / Share (Annual)$6.37

3-Month Return Std Dev103.24%

Net Income / Employee (TTM)$-4,207,700

ROE (Last FY)-279.29%

Net Interest Coverage (Annual)-44.71x

EPS Basic Excl Extra (Annual)$-11.28

Receivables Turnover (TTM)9.33x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-7.93

ROI (TTM)-216.75%

P/S Ratio (TTM)24.51x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-0.82

Price vs S&P 500 (52W)-102.17%

Year-to-Date Return-74.17%

5-Day Price Return-1.90%

EPS Normalized (Annual)$-11.28

ROA (5Y Avg)-169.91%

Net Profit Margin (Annual)0.00%

Month-to-Date Return-3.73%

Cash Flow / Share (TTM)$-9.31

EBITD / Share (Annual)$-11.59

Operating Margin (Annual)0.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-130.36%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-7.93

P/TBV (Quarterly)11.06x

P/B Ratio (Annual)1.20x

Pretax Margin (TTM)-3.57%

Book Value / Share (Annual)$4.80

Price vs S&P 500 (13W)-72.82%

Beta3.13x

Revenue / Share (TTM)$0.00

ROE (TTM)-217.27%

52-Week Low$1.50

mGradeF

vgmGradeF

SKYE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$2.11	-$1.55	+26.19%(+$0.55)
Q1 2026	May 11, 2026	-$2.59	-$2.56	+1.03%(+$0.03)
Q4 2025	Mar 10, 2026	-$2.45	-$2.95	-20.20%(-$0.50)
Q3 2025	Nov 10, 2025	-$2.56	-$2.59	-1.22%(-$0.03)
Q2 2025	Aug 7, 2025	-$0.30	-$0.45	-48.90%(-$0.15)

SKYE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.07

4.00

3.92

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SKYESkye Bioscience, Inc. Common Stock	—	—	F	24.5x	—	39.3%	—	$1.55
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Skye Bioscience, Inc. Common Stock

Skye Bioscience is a San Diego-based pharmaceutical company developing CB1 receptor-targeted therapies for metabolic and inflammatory disorders. Lead candidates in Phase 2 are nimacimab for obesity and SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension. The platform also targets fibrotic and neurodegenerative diseases.

SKYE Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

EPS estimate-$1.12

Revenue estimate$0

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

SKYE Insider Transactions

SellSep 23, 2026
SCHWAB ANDREW J.
Director and Beneficial Owner of more than 10% of a Class of Security
Shares: 148,079Value: $239,555
SellSep 23, 2026
5AM PARTNERS VII, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 148,079Value: $239,555
SellAug 20, 2026
SCHWAB ANDREW J.
Director and Beneficial Owner of more than 10% of a Class of Security
Shares: 375,840Value: $140,313
SellAug 20, 2026
5AM PARTNERS VII, LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 375,840Value: $140,313

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

BMRABIOMERICA INCIn Vitro Diagnostics
FRTTFort Technology Inc. Common SharesAgricultural Chemicals
NAIINatural Alternatives International Inc.Pharmaceutical Preparations
SNTISenti Biosciences Holdings, Inc. Common StockBiological Products
AIMAIM ImmunoTech Inc.Biological Products
BIOTInstinct Bio Technical Company Holdings Inc. Ordinary SharesCosmetics & Toiletries
TRIBTrinity Biotech plcIn Vitro Diagnostics
EVGNEVOGENE LTD.Agricultural Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$1.50

High$13.28